Exagen Inc.
XGN · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.66 | 0.00 | 0.17 | -0.04 |
| FCF Yield | -2.10% | -16.19% | 0.29% | -4.12% |
| EV / EBITDA | -45.64 | -21.85 | -27.41 | -14.25 |
| Quality | ||||
| ROIC | -5.19% | -10.82% | -10.31% | -12.84% |
| Gross Margin | 60.43% | 58.87% | 62.08% | 55.82% |
| Cash Conversion Ratio | -0.42 | 0.65 | 2.84 | -0.10 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.20% | 3.60% | 6.93% | 6.89% |
| Free Cash Flow Growth | 71.31% | -5,069.59% | 109.34% | 9.33% |
| Safety | ||||
| Net Debt / EBITDA | 10.32 | 2.23 | -0.48 | -0.31 |
| Interest Coverage | -2.34 | -6.17 | -6.01 | -8.30 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 1.88 |
| Cash Conversion Cycle | 41.48 | 21.87 | -20.27 | 97.34 |